First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy: Figure 1
Abstract
We report a case of a 68 year old woman with multiple local recurrences of a rectal GIST, first operated on 13 years earlier, and who now presented with four adjacent masses located in the rectovaginal septum and no distant metastasis. Molecular analysis identified a 6 bp deletion in exon 11 of the c-kit proto-oncogene. As curative surgery would have implied abdominoperineal resection with permanent colostomy, treatment with imatinib at a standard dose (400 mg/day) was started. Response to treatment was evaluated using endorectal ultrasound and magnetic resonance imaging every three months. Quantification of tumour mass was obtained by adding the products of two perpendicular axes of the two major lesions. Maximal response was obtained at nine months, which was maintained after 12 months of treatment. At that time, total tumour mass reduction was 83%, which was enough to allow rectal resection with a coloanal anastomosis (fig 1A, B). Pathological analysis of the surgical specimen identified four white firm masses with diameters ranging from 1 to 2 cm. These lesions were composed of hyaline connective tissue, which did not stain with either CD34 or CD117, and no viable tumour cells were identified in the whole specimens (fig 1C–E). Imatinib was suspended and after 24 months of follow up there is no evidence of local or distant recurrence. This is, to our knowledge, the first report of a complete pathological response of a GIST treated with imatinib.Keywords
This publication has 6 references indexed in Scilit:
- Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMOAnnals of Oncology, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumorsGastroenterology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.2001
- Gastrointestinal Stromal Tumors: Current Diagnosis, Biologic Behavior, and ManagementAnnals of Surgical Oncology, 2000